Marché Fermé -
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
6,93 USD | +6,62% | +5,96% | +17,86% |
26/02 | COGENT BIOSCIENCES, INC. : Citigroup réitère son opinion positive sur le titre | ZM |
26/02 | Cogent Biosciences, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023 | CI |
Métier
Nombre d'employés: 164
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Andrew Robbins
CEO | Chief Executive Officer | 48 | 23/10/20 |
John Green
DFI | Director of Finance/CFO | 43 | 01/06/18 |
Rachael Easton
CTO | Chief Tech/Sci/R&D Officer | - | 28/11/22 |
Brad Barnett
CTO | Chief Tech/Sci/R&D Officer | - | - |
Jessica Sachs
CTO | Chief Tech/Sci/R&D Officer | 49 | 01/04/17 |
John Robinson
CTO | Chief Tech/Sci/R&D Officer | 50 | 06/04/21 |
Christi Waarich
IRC | Investor Relations Contact | - | - |
Dana Martin
PRN | Corporate Officer/Principal | - | 01/11/21 |
Sara Saltzman
LAW | General Counsel | - | 01/01/19 |
Human Resources Officer | - | - |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 26/07/19 |
Matthew Ros
BRD | Director/Board Member | 57 | 26/07/19 |
Todd Shegog
BRD | Director/Board Member | 59 | 22/02/21 |
Karen Ferrante
BRD | Director/Board Member | 66 | 01/02/18 |
Andrew Robbins
CEO | Chief Executive Officer | 48 | 23/10/20 |
Peter Harwin
CHM | Chairman | 38 | 06/07/20 |
Chris Cain
BRD | Director/Board Member | 40 | 06/07/20 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 95 613 396 | 94 354 142 ( 98,68 %) | 0 | 98,68 % |
Action B | 0 | 74 465 | 0 | 0 |
Coordonnées société
Secteur
Révisions de BNA
Varia. 1 janv. | Capi. | |
---|---|---|
+17,86% | 663 M | |
-1,17% | 104 Md | |
+2,87% | 97,47 Md | |
+3,76% | 22,25 Md | |
-14,77% | 21,68 Md | |
-9,00% | 18,2 Md | |
-39,98% | 17,02 Md | |
-13,21% | 16,36 Md | |
+8,55% | 14,39 Md | |
+35,75% | 12,37 Md |
- Bourse
- Actions
- Action COGT
- Société Cogent Biosciences, Inc.